

Akums' patented 'Tablet-in-Tablet' technology brings relief for expectant mothers

06 May 2025 | News

A significant step forward in addressing a longstanding gap in maternal healthcare



Akums Drugs & Pharmaceuticals, one of India's leading pharmaceutical contract research and manufacturing organisation (CDMO), has been granted a patent for its breakthrough extended-release formulation of Doxylamine and Pyridoxine, designed specifically to address Nausea and Vomiting in Pregnancy (NVP).

Nausea and vomiting of pregnancy (NVP) is one of the most common conditions experienced by expectant mothers, affecting up to 80% of women to varying degrees. While many women find relief by the 16th week, about 20% continue to suffer throughout their pregnancy. NVP can significantly disrupt daily routines, nutrition, and overall well-being.

In response, Akums has developed a ground-breaking patented formulation that offers a solution designed to provide longer-lasting relief. This innovation marks a significant step forward in addressing a longstanding gap in maternal healthcare, offering much-needed support to those impacted by this common pregnancy challenge.

This unique dosage form combines an outer layer that provides immediate drug release for rapid relief from nausea, with an inner core designed for sustained release, ensuring a longer therapeutic effect. The outer layer provides rapid relief from nausea, while the inner core maintains a prolonged action, reducing the need for frequent dosing.

By combining immediate and sustained release in a single tablet, this dual-action design not only improves treatment outcomes but also enhances patient compliance, an essential factor in pregnancy care where safety, simplicity, and consistency are critical.

Following a rigorous bioequivalence study and successful approval from the Drug Controller General of India (DCGI), the extended-release formulation stands validated in terms of efficacy and safety.